LUCIUS 卢修斯 维罗非尼 Vemurafenib黑色素瘤

维罗非尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Vemurafenib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Fach film-coated tablet contains

黑色素瘤

Vemurafenib ..........

LUCIUS

Indication:

PHARMACEUTICALS

LciVemu is a kinase inhibitor indicated for the
trentment of patients with unresectable or metastatic
melanoma with BRAF V600E mutation as detected
by an FDA-approved TeSt.
LuciVemu is indicated for the treatment of patients
with Erdheim-Chester Disease with BRAF V600

LuciVemu

mutation.
Dosage and Use:
"Confirm the presence of BRAF V600E mutatio
rspecimens prior to initiation of freatment
with LuciVemu.

Vemurafenib Tablets 240mg

FDA批准

Recommended dose:960 mg orally twice daily
taken approximately 12 hours apart with or without

a meal

Storage: in a dry place and store at 20°C to 25°C ..

56 Tablets

Warnine

Keep medicine out of reach of Children. Do not
administer LuciVemu during Pregnancy and
Lactation

PLEASE SEE PACKAGE INSERT

Rx Only

Manufactured and Marketed by
LUCIUS

权威认证

Thongmang village, Xaythany district,
Vientiane Capital, Laos
www.lucius.la
Warning: To he sold by retanl on orcscopko
of registered alvsicians only, and as directed

Dy the physician

口碑质量

适应症:
1、适用于治疗经FDA批准的测试方法检测为BRAFV600E
突变的不可切除或转移性黑色素瘤患者。
2、适用于治疗BRAFV600突变的Erdheim-Chester病患者。
推荐剂量:
每日口服两次,每次960mg(4片),间隔约12小时,随餐或
空腹均可。